Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$160.21 USD

160.21
862,640

+0.52 (0.33%)

Updated Oct 9, 2024 11:18 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 13% (33 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sweta Killa headshot

Will Dow ETFs Continue to Shine in Q3 Earnings?

by Sweta Killa

The Dow Jones has returned 24.2% since the Election Day compared to a gain of 18.9% for the S&P 500.

    Here's What's Has Happened in the HCV Space Lately

    by Zacks Equity Research

    A lot has happened in the hepatitis C virus space of late. The market is getting crowded and seeing increased pricing pressure.

      Johnson & Johnson Files sNDA for Label Expansion of Invokana

      by Zacks Equity Research

      Johnson & Johnson (JNJ) filed a supplemental New Drug Application to the FDA for the label expansion of Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular events in adults with type II diabetes.

        Integra Closes Codman Buyout, Strengthens Neurosurgery Arm

        by Zacks Equity Research

        With Codman's acquisition by Integra (IART), the neurosurgery business is likely to drive the company's 2018 adjusted earnings per share with a minimum yield of 22 cents.

          Arpita Dutt headshot

          Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs?

          by Arpita Dutt

          With Merck (MRK) discontinuing the development of two HCV candidates, here's a look at what to expect from the remaining key players in the HCV market.

            The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO

            by Zacks Equity Research

            The Zacks Analyst Blog Highlights: Flexion Therapeutics, Alexion Pharmaceuticals, PTC Therapeutics, Johnson & Johnson and TESARO

              Abbott Gets FDA Nod for FreeStyle Libre, Boosts Diabetes Arm

              by Zacks Equity Research

              Abbott's (ABT) diabetes care segment to strengthen with the FDA approval for FreeStyle Libre Flash glucose monitoring system.

                Arpita Dutt headshot

                3 Biotech and Pharma Stocks with Key FDA Catalysts this October

                by Arpita Dutt

                Here is a look at three biotech and pharma stocks including Flexion (FLXN) that have an important regulatory event lined up this month.

                  Merck Drops Two HCV Combination Programs Amid Competition

                  by Zacks Equity Research

                  Merck (MRK) is discontinuing the development of two of its hepatitis C (HCV) programs - MK-3682B and MK-3682C - as the HCV market is becoming extremely crowded.

                    Quality Dividend ETFs for Turbulent Times

                    by Zacks Equity Research

                    Consider these 3 dividend ETFs for your portfolio to fight rising market uncertainty.

                      How Will Trump's Proposed Tax Reform Impact Drug Companies?

                      by Zacks Equity Research

                      Donald Trump has proposed new tax reforms for individuals and corporates. Let's see how the reforms, if passed, will impact pharma companies.

                        The Zacks Analyst Blog Highlights: Goldman Sachs Group, PepsiCo, Johnson & Johnson, Cummins and Fidelity National Information Services

                        by Zacks Equity Research

                        The Zacks Analyst Blog Highlights: Goldman Sachs Group, PepsiCo, Johnson & Johnson, Cummins and Fidelity National Information Services

                          Impax Generic Division Progresses Well Amid Pricing Pressure

                          by Zacks Equity Research

                          Impax Laboratories' (IPXL) generic portfolio has progressed well so far this year. Moreover, approval of the generic versions of Vytorin and Concerta is a positive.

                            Mark Vickery headshot

                            Top Stock Reports for Goldman Sachs, PepsiCo and Johnson & Johnson

                            by Mark Vickery

                            Today's Research Daily features new research reports on 12 major stocks, including Goldman Sachs Group Inc (GS), PepsiCo, Inc. (PEP) and Johnson & Johnson (JNJ)

                              J&J's Arthritis Candidate Sirukumab Denied FDA Approval

                              by Zacks Equity Research

                              J&J (JNJ) said that the FDA has denied approval to its investigational rheumatoid arthritis treatment, sirukumab for want of additional safety data.

                                Allergan's (AGN) Vraylar Gets RTF From FDA, New Data for CVC

                                by Zacks Equity Research

                                The FDA slaps a refusal-to-file letter on Allergan's (AGN) Vraylar for its supplemental New Drug Application. The company tries to expand the drug???s label for its use as a maintenance treatment.

                                  Here's Why These 3 Biotech Stocks Might Stop Rallying (Revised)

                                  by Zacks Equity Research

                                  The momentum in the biotech sector is likely to continue. However, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant gains year to date.

                                    Karyopharm's Liposarcoma Candidate Superior in Phase II Study

                                    by Zacks Equity Research

                                    Karyopharm's (KPTI) selinexor reduced the risk of progression or death in previously treated patients with advanced dedifferentiated liposarcoma.

                                      Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake

                                      by Zacks Equity Research

                                      Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.

                                        Here's Why These 3 Biotech Stocks Might Stop Rallying

                                        by Zacks Equity Research

                                        The momentum in the biotech sector is likely to continue. However, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant gains year to date.

                                          Top Research Reports for Northrop Grumman, BNY Mellon & Celgene

                                          by Zacks Equity Research

                                          Today's Research Daily features new research reports on 16 major stocks, including Northrop Grumman (NOC), Bank of New York Mellon (BK) and Celgene (CELG)

                                            Alkermes' ARISTADA Shows Better Results to Treat Schizophrenia

                                            by Zacks Equity Research

                                            Alkermes (ALKS) announced encouraging results from a phase IV study of ARISTADA for the treatment of schizophrenia.

                                              Catalyst (CPRX) Focused on Two Lead Pipeline Candidates

                                              by Zacks Equity Research

                                              : Catalyst (CPRX) remains focused on development of its two lead pipeline candidates, Firdapse and CPP-115.

                                                J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU

                                                by Zacks Equity Research

                                                J&J's (JNJ) pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis received a positive opinion from the CHMP in the EU.

                                                  Neos Therapeutics ADHD Drug Adzenys Receives Approval in US

                                                  by Zacks Equity Research

                                                  Neos Therapeutics (NEOS) announced the approval of its third ADHD drug Adzenys for the treatment of six years and older patients.